Significant Potential for Growth Underlines Therapeutic Cancer Vaccines

Therapeutics cancer vaccine market in the US poses significant potential for growth and evolution, says RNCOS.

Noida, India (prHWY.com) November 12, 2012 - A new research report from RNCOS reveals that the therapeutics cancer vaccine market in the US poses significant potential for growth and evolution. It is anticipated that the share of therapeutic vaccines will increase drastically with several therapeutic vaccines in pipeline (R&D) and the market is expected to see promising new market entrants. Some of these therapeutic vaccines have also shown promising results in trials and have entered the Phase-3 stages. In 2012, share of therapeutic vaccines is expected to grow by 15%. The growing diseases and requirement for specialized drugs and vaccines is driving the pharma market and will be the major reason for growth in therapeutic cancer vaccines too.

The cancer vaccine market is composed of prophylactics and therapeutic vaccines. The prophylactic vaccines currently available in the market include Merck's Gardasil, GSK's Cervarix, and several other Hepatitis B vaccines while the only therapeutic vaccine in the market is Dendreon's Provenge. Amongst the several cancers, lung cancer is expected to see a marketable product soon, as more than 30% of the therapeutic cancer vaccines in phase-3 clinical trials are for the treatment of lung cancer. The US represents the most promising market for cancer vaccines across the globe and our regional level analysis revealed that California led in terms of the total number of new cancer cases followed by Florida, Texas and New York.

The report entitled, "US Cancer Vaccine Market Analysis", provides an analysis of the market drivers, current market size, and future estimates. It also provides the key constraints faced by these cancer vaccine products that can hinder its market growth in the future. Moreover, an in-depth analysis of all the candidate cancer vaccines in various phases of clinical trials for most prevalent cancers in the US has been covered to identify diverse opportunities for players. Further, the report provides competitive analysis of the promising players in the market along with their key strategies for business expansion. The regulatory environment detailing the whole cancer vaccine approval process along with FDA's guidelines to the industry for clinical proceedings of cancer therapeutic vaccines has also been covered in this report.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM457.htm

Some of our Related Reports are:

- Global Vaccine Market Forecast to 2013 (http://www.rncos.com/Report/IM357.htm)
- Global Influenza Vaccine Market Analysis (http://www.rncos.com/Report/IM356.htm)
- Global Vaccine Market Forecast to 2012 (http://www.rncos.com/Report/IM153.htm)

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

About RNCOS

RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.

###

Tag Words: us cancer vaccine market

Categories: Biotech

Press Release Contact
B-129, Sector 6 Noida - 201301
91-120-4224-700
91-120-4224-707

Link To This Press Release:

URL HTML Code